Macimorelin
AEZS-130 · Macrilen · oral GH test
FDA-approved oral AGHD diagnostic (Macrilen). Single fasted dose with timed GH draws. Not MK-677, not a daily secretagogue, and this database has no SubQ vial.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Sexual / hormonal7/10
Approved diagnostic for adult GHD. Ceiling 9 for approval; haircut because this leaf is a test, not replacement therapy.
Compound card
- Sequence
- Oral ghrelin-mimetic peptidomimetic (AEZS-130)
- Class
- FDA-approved AGHD diagnostic (Macrilen); not a daily GH protocol
- Formula
- C26H32N6O3
- Status
- FDA-approved
How it works
Macimorelin (AEZS-130) is a peptidomimetic ghrelin receptor agonist - an orally active synthetic compound that mimics ghrelin binding at GHS-R1a on pituitary somatotroph cells. Unlike ghrelin itself (28 amino acids, SubQ only), macimorelin is orally bioavailable with ~90% GHS-R1a receptor selectivity.
Macimorelin is FDA-approved (Macrilen) specifically for diagnosis of adult growth hormone deficiency (AGHD). A single oral dose (0.5 mg/kg) reliably stimulates a GH peak, providing a safe, patient-friendly alternative to the insulin tolerance test (ITT) or arginine stimulation test. Off-label, it is being explored for recovery of GH axis function, though its primary use is diagnostic.
Source: FDA Label (Macrilen), PMID: 30011461
Background & History
Macimorelin is an FDA-approved oral AGHD diagnostic (Macrilen). Single fasted dose with timed GH draws. Not MK-677, not a daily secretagogue, and this database has no SubQ vial.
Research Use Cases
- ✓Macrilen diagnostic identity vs ibutamoren
- ✓Why a one-shot GH stim test is not a bedtime protocol
- ✓Not a biohack oral GHRP
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Diagnostic (FDA-approved) | 0.5 mg/kg | Single oral dose (diagnostic only) | FDA-approved for GHD diagnosis. Blood draw at baseline and 30/45/60 min post-dose. GH <2.8 ng/mL = GHD. |
Administration
Timeline
Who it is for
GHD Diagnosis
HighFDA-approved diagnostic agent. Replaces invasive insulin tolerance test. Single oral dose protocol.
Safety & Considerations
FDA-approved (Macrilen). Single-dose diagnostic use. Well-tolerated. May cause dizziness, nausea, or hunger (ghrelin effects). Not for therapeutic use in current approved form.
Regulatory & Legal Status
FDA-approved as Macrilen® for diagnosis of adult growth hormone deficiency
Competitive athletes subject to anti-doping controls should not use Macimorelin.
Prescription Drug
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- 0.5 mg/kg once, fasted, with timed GH draws. That is the label.
- Off-label “oral GH optimization” is not Macrilen.
- Empty commonVialSizes. No reconstitution table.
Verdict
Macimorelin is Macrilen, a single-dose oral GH stimulation test. It is not MK-677, not a bedtime secretagogue, and this database has no daily vial. Do not force it into the SubQ calculator.
Interactions & Contraindications
Labeled fasting and CYP3A4 cautions belong to the diagnostic. Fatty meals blunt the peak. Not a chronic GH-optimization drug.
Synergies & Common Stacks
Same receptor family. Do not stack a diagnostic with a daily GHRP.
Frequently Asked Questions
What is macimorelin used for?▼
Can macimorelin be used to boost GH therapeutically?▼
References
- Garcia JM et al. “"Macimorelin for diagnosis of adult growth hormone deficiency".” JCEM (2018). PMID: 29272514
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code